«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

31卷

期数:

2025年03期

页码:

251-256

栏目:

基础医学

出版日期:

2025-05-20

文章信息/Info

Title:

Feasibility analysis of morphological methods in the detection of chimeric antigen receptor-T cells

文章编号:

1006-8147(2025)03-0251-06

作者:

马立; 江嫣雨; 赵明峰

（天津市第一中心医院血液科，天津300384）

Author(s):

MA Li; JIANG Yanyu; ZHAO Mingfeng

（Department of Hematology，Tianjin First Central Hospital，Tianjin 300384，China）

关键词:

嵌合抗原受体-T细胞; 形态学方法; 检测方法

Keywords:

chimeric antigen receptor-T cell; morphological methods; detection methods

分类号:

R446.11

DOI:

10.20135/j.issn.1006-8147.2025.03.0251

文献标志码:

A

摘要:

目的：为了减少单一检测方法的局限性，探讨形态学方法在嵌合抗原受体（CAR）-T细胞检测应用中的可行性。方法：分析106例应用CAR-T免疫方法治疗的病例，比较形态学检测到的CAR-T与输注物中和流式细胞分选获得的CAR-T细胞形态。通过流式细胞术（FCM）和形态学方法分别检测各个时间点外周血或骨髓标本CAR-T比例，采用统计学方法对两种方法检测结果进行比较，以评估形态学方法检测结果的可靠性。结果：形态学检测到的CAR-T与上述两种CAR-T形态特征一致。Spearman相关性分析结果显示在各个检测时间点，外周血或骨髓标本通过2种方法检测结果均具有相关性（rs＞0.3），其中除第2天、第28天外结果具有高度相关性（rs>0.8，P<0.01）；Wilcoxon秩和检验显示除第2天、第28天外其余检测时间点检测结果差异无统计学意义（P>0.05）；选取扩增高峰的外周血标本进行一致性分析，结果示第10天有103组数据在95%可信区间内，第14天有102组数据在95%可信区间内，一致性较好；两种方法联合检测检出率为99.06%，高于仅单一使用FCM方法（检出率81.13%），差异有统计学意义（?字2=16.433，P<0.05）。结论：形态学方法在CAR-T检测中应用是可行的，作为FCM方法的补充方法弥补了单一检测方法的不足。

Abstract:

Objective： To reduce the limitations of a single detection method，the feasibility of morphological methods in chimeric anti-gen receptor （CAR）-T cell detection was investigated. Methods：A total of 106 cases treated with CAR-T immunotherapy were ana-lyzed. The morphology of CAR-T cells detected by morphological methods with those in the infusion product and obtained through flow cytometry sorting was compared. The proportion of CAR-T in peripheral blood or bone marrow samples at various time points was detect-ed by flow cytometry （FCM） and morphological methods，and the results were compared by statistical methods to assess the reliability of the morphological detection results. Results：The morphological characteristics of CAR-T detected by morphological methods were consistent with those of the two types of CAR-T mentioned above. The Spearman correlation analysis results indicated that there was a correlation between the detection results obtained by the two methods for peripheral blood or bone marrow samples at various time points （rs＞0.3），and except for the results on the 2th day and on the 28th day，all other results had a high correlation （rs>0.8，P<0.01）；Wilcoxon rank-sum test showed that there was no statistically significant difference in the detection results at the remaining time except for those on the 2th day and on the 28th day （P>0.05）. The peripheral blood samples at the peak of amplification were selected for consistency analysis，the results indicated that on the 10th day，103 sets of data were within the 95% confidence interval，and on the 14th day，102 sets of data were within the 95% confidence interval，showing good consistency. The detection rate of the combination of the two methods was 99.06%，which was higher than that of the single FCM method （detection rate was 81.13%），and there was statistically significant differ-ence （ ?字2=16.433，P<0.05）. Conclusions：The application of morphological methods in CAR-T detection is feasible，and as a comple-mentary method to FCM，it compensates for the shortcomings of a single detection method.

参考文献/References:

[1] LUSKIN M R，DEANGELO D J.Chimeric antigen receptor therapy in acute lymphoblastic leukemia clinical practice[J]. Curr Hematol Malig Rep，2017，12（4）：370-379.
[2] MAROFI F，RAHMAN H S，AL-OBAIDI Z，et al. Novel CAR-T therapy is a ray of hope in the treatment of seriously ill AML patients[J]. Stem Cell Res Ther，2021，12（1）：465.
[3] JAIN T，BAR M，KANSAGRA A J，et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-hodgkin lymphoma：an expert panel opinion from the American Society for Transplantation and Cellular Therapy[J]. Biol Blood Marrow Transplant，2019，25（12）：2305-2321.
[4] HOFMANN S，SCHUBERT M L，WANG L，et al. Chimeric Antigen Receptor（CAR）-T cell therapy in acute myeloid leukemia（AML）[J]. J Clin Med，2019，8（2）：200.
[5] GOMES-SILVA D，ATILLA E，ATILLA P A，et al. CD7 CAR-T cells for the therapy of acute myeloid leukemia[J]. Mol Ther，2019， 27（1）：272-280.
[6] PORTER D L，HWANG W T，FREY N V，et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia[J]. Sci Transl Med，2015，7（303）：303ra139.
[7] 中国中西医结合学会检验医学专业委员会. 流式细胞术在嵌合抗原受体-T细胞免疫治疗相关检验中的应用专家共识[J]. 中华检验医学杂志，2022，45（8）：790-801.
[8] SARIKONDA G ，MATHIEU M ，NATALIA M ，et al. Best practices for the development，analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses[J]. Cytometry B Clin Cytom，2021，100（1）：79-91.
[9] ZHOU L，LIU X，WANG X，et al. CD123 redirected multiple viru-sspecific T cells for acute myeloid leukemia[J]. Leuk Res，2016， 41：76-84.
[10] LYNN R C，FENG Y，SCHUTSKY K，et al. High-affinity FRβ-specific CAR-T cells eradicate AML and normal myeloid lineage without HSC toxicity[J]. Leukemia，2016，30（6）：1355-1364.
[11] WANG S J，WEI W W，YUAN Y C，et al. Chimeric antigen receptor T cells targeting cell surface GRP78 efficiently kill glioblastoma and cancer stem cells[J]. J Transl Med，2023，21（1）：493-498.
[12] 胡丽华，陈万新主编. 临床血液细胞形态学图谱[M]. 北京：人民卫生出版社，2020：390-392.
[13] STERNER R M，SAKEMURA R，COX M J，et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts[J]. Blood，2019，133（7）：697-709.
[14] LIU Y，FANG Y，CHEN X，et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome[J]. Sci Immunol，2020，5（43）：eaax7969.
[15] 孙增田，张猛，闫冬梅，等. 形态学与流式细胞术联合检测嵌合抗原受体-T细胞方法探究[J]. 中华检验医学杂志，2022，45（8）：820-824.

相似文献/References:

备注/Memo

备注/Memo:

基金项目: 天津市医学重点学科（专科）建设项目（TJYXZDXK-056B）；天津市自然科学基金青年项目（22JCQNJC00820）
作者简介: 马立（1979-），女，主管技师，学士，研究方向：临床血液检验；
通信作者：赵明峰，E-mail：mingfengzhao@sina.com。

常用功能

更新日期/Last Update: 2025-06-01